ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Onconetix (ONCO)
Onconetix stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.47▲ +16.64%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
42%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Onconetix in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Onconetix
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Onconetix a 42% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.35 and $0.55; in 9 out of 10, between $0.23 and $0.84. Estimated annual volatility is 144%.
Key numbers
- Revenue (12 months)
- $0.6M
- Revenue growth (YoY)
- -67.7%
- Gross margin
- 77.6%
- Return on equity
- -105.2%
- Free cash flow (12 months)
- $-5.9M
- Beta
- 2.68
What this means
ATLAS does not publish a fair value for ONCO right now, but it does show its odds of rising: somewhat worse than a coin flip.
Its beta is 2.68: it tends to move more than the market, both up and down.
About the company
Onconetix Inc. is a commercial-stage biotechnology company focused on solutions for men’s health and oncology. The company develops and commercializes proprietary therapeutics, diagnostics, and clinician-focused services, with an emphasis on prostate cancer and related urologic conditions.
Want to see everything about Onconetix?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does Onconetix do?
Onconetix Inc. is a commercial-stage biotechnology company focused on solutions for men’s health and oncology. The company develops and commercializes proprietary therapeutics, diagnostics, and clinician-focused services, with an emphasis on prostate cancer and related urologic conditions.
What is the chance ONCO goes up next month?
42%: somewhat worse than a coin flip. In half of the simulated outcomes, ONCO ends the month between $0.35 and $0.55.
How volatile is ONCO?
ATLAS estimates annual volatility at 144%. In a typical month, half of the outcomes end between $0.35 and $0.55.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer